CO64 Challenges Associated with Surrogate Endpoints for Healthcare Decision Making in Oncology

With the continuous emergence of new technologies filling high unmet medical needs in oncology, accelerated time to market for earlier patient access has gained importance. Increasing costs of drug development and intense competition between treatment options have enhanced the desire for early market access using surrogate endpoints. No study has recently assessed the use of surrogate endpoints in oncology and how this affects a new product in development. This research aims to identify the key challenges associated with surrogate endpoints in oncology from a payer perspective and provide recommendations to ensure an optimal Health Technology Assessment (HTA) submission.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research